Abstract
The aim of this article is to focus on the fixed-dose combination of phentermine and topiramate, a new antiobesity drug recently approved by the US FDA. The mechanisms of weight loss for each drug in monotherapy is described, followed by the rationale for its use as a combination therapy and a comprehensive review of recently published clinical trials that assessed its efficacy and safety.
MeSH terms
-
Anti-Obesity Agents / therapeutic use*
-
Appetite Depressants / therapeutic use*
-
Dose-Response Relationship, Drug
-
Drug Combinations
-
Fructose / analogs & derivatives*
-
Fructose / therapeutic use
-
Humans
-
Obesity / drug therapy*
-
Phentermine / therapeutic use*
-
Randomized Controlled Trials as Topic
-
Topiramate
-
Treatment Outcome
Substances
-
Anti-Obesity Agents
-
Appetite Depressants
-
Drug Combinations
-
Topiramate
-
Fructose
-
Phentermine